Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 3;10(8):1879.
doi: 10.3390/biomedicines10081879.

Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer's Disease

Ioanna Tsantzali  1 , Aikaterini Foska  1 , Eleni Sideri  1 , Evdokia Routsi  1 , Effrosyni Tsomaka  1 , Dimitrios K Kitsos  1 , Christina Zompola  1 , Anastasios Bonakis  1 , Sotirios Giannopoulos  1 , Konstantinos I Voumvourakis  1 , Georgios Tsivgoulis  1 , George P Paraskevas  1
Affiliations

Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer's Disease

Ioanna Tsantzali et al. Biomedicines. .

Abstract

Cerebrospinal fluid (CSF) biomarkers remain the gold standard for fluid-biomarker-based diagnosis of Alzheimer's disease (AD) during life. Plasma biomarkers avoid lumbar puncture and allow repeated sampling. Changes of plasma phospho-tau-181 in AD are of comparable magnitude and seem to parallel the changes in CSF, may occur in preclinical or predementia stages of the disease, and may differentiate AD from other causes of dementia with adequate accuracy. Plasma phospho-tau-181 may offer a useful alternative to CSF phospho-tau determination, but work still has to be done concerning the optimal method of determination with the highest combination of sensitivity and specificity and cost-effect parameters.

Keywords: Alzheimer’s disease; biomarkers; cerebrospinal fluid; phospho-tau; plasma.

PubMed Disclaimer

Conflict of interest statement

G.P.P. has received fees from Biogen International as a consultant of advisory board. All other authors none.

References

    1. Blennow K., Zetterberg H. Biomarkers for Alzheimer’s disease: Current status and prospects for the future. J. Intern. Med. 2018;284:643–663. doi: 10.1111/joim.12816. - DOI - PubMed
    1. Dubois B., Feldman H.H., Jacova C., Hampel H., Molinuevo J.L., Blennow K., DeKosky S.T., Gauthier S., Selkoe D., Bateman R., et al. Advancing research diagnostic criteria for Alzheimer’s disease: The IWG-2 criteria. Lancet Neurol. 2014;13:614–629. doi: 10.1016/S1474-4422(14)70090-0. - DOI - PubMed
    1. Simonsen A.H., Herukka S.K., Andreasen N., Baldeiras I., Bjerke M., Blennow K., Engelborghs S., Frisoni G.B., Gabryelewicz T., Galluzzi S., et al. Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimers Dement. 2017;13:274–284. doi: 10.1016/j.jalz.2016.09.008. - DOI - PubMed
    1. Jack C.R., Jr., Bennett D.A., Blennow K., Carrillo M.C., Dunn B., Haeberlein S.B., Holtzman D.M., Jagust W., Jessen F., Karlawish J., et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–562. doi: 10.1016/j.jalz.2018.02.018. - DOI - PMC - PubMed
    1. McGrowder D.A., Miller F., Vaz K., Nwokocha C., Wilson-Clarke C., Anderson-Cross M., Brown J., Anderson-Jackson L., Williams L., Latore L., et al. Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives. Brain Sci. 2021;11:215. doi: 10.3390/brainsci11020215. - DOI - PMC - PubMed

LinkOut - more resources